Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Within- and between-group changes in body composition outcomes over 12 weeks

From: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

Outcome Baseline Week 12 Within-group mean change over 12 weeksa Between-group mean change over 12 weeksb
n Mean ± SD n Mean ± SD Mean (95% CI) Mean (95% CI) P
Lean Mass (kg)
 EXE 16 48.5 ± 5.4 13 53.2 ± 7.3 1.1 (0.4, 1.8) 1.1 (0.02, 2.2) 0.05
 NoEXE 19 51.5 ± 7.6 19 48.6 ± 5.8 0.1 (−0.5, 0.7)   
Appendicular skeletal mass (kg)
 EXE 16 23.5 ± 4.7 13 24.8 ± 4.6 0.8 (0.4, 1.2) 0.7 (0.1, 1.3) 0.03
 NoEXE 19 21.5 ± 2.6 19 21.6 ± 2.9 0.1 (−0.3, 0.4)   
Sarcopenic index (kg/m2)
 EXE 16 8.1 ± 1.5 13 8.5 ± 1.6 0.3 (0.2, 0.4) 0.3 (0.1, 0.5) 0.02
 NoEXE 19 7.3 ± 0.8 19 7.3 ± 0.9 0.01 (−0.1, 0.1)   
Fat Free Mass (kg)
 EXE 16 54.6 ± 7.9 13 56.4 ± 7.5 1.0 (0.4, 1.8) 1.1 (0.1, 2.2) 0.04
 NoEXE 19 51.4 ± 5.7 19 51.5 ± 6.0 0.1 (−0.5, 0.7)   
Body Fat (%)
 EXE 16 36.8 ± 5.1 13 35.9 ± 5.6 −0.9 (−1.8, − 0.01) − 1.7 (−2.9, − 0.6) 0.01
 NoEXE 19 33.9 ± 5.9 19 34.5 ± 5.3 0.5 (−0.2, 1.2)   
Fat Mass (kg)
 EXE 16 30.3 ± 10.5 13 31.2 ± 11.6 −0.3 (−1.2, 0.6) −0.7 (−2.0, 0.6) 0.26
 NoEXE 19 25.6 ± 8.3 19 26.2 ± 8.0 0.6 (−1.5, 1.3)   
Total Mass (kg)
 EXE 16 85.0 ± 17.8 13 87.5 ± 18.8 0.8 (−0.5, 2.0) 0.3 (−1.5, 2.1) 0.75
 NoEXE 19 77.0 12.1 19 77.7 ± 12.4 0.7 (−0.3, 1.7)   
  1. Data presented as mean ± standard deviation. P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH)
  2. aEXE relative to NoEXE adjusted for baseline values
  3. bEXE relative to NoEXE adjusted for baseline values, protein supplementation, body mass index and number of comorbidities